Baseline patient demographics and clinical characteristics
CP-870,893 Dose cohort | |||
---|---|---|---|
0.1 mg/kg (n = 3) | 0.2 mg/kg (n = 6) | MTD expansion 0.2 mg/kg (n = 13) | |
Characteristic | n (%) | n (%) | n (%) |
Age, y | |||
Median | 59 | 59 | |
Range | 57–72 | 40–81 | |
Sex | |||
Male | 2 (67) | 3 (50) | 9 (69) |
Female | 1 (33) | 3 (50) | 4 (31) |
Race/ethnicity | |||
White | 0 (0) | 5 (83) | 11 (84) |
Black | 3 (100) | 1 (17) | 1 (8) |
Asian | 0 (0) | 0 (0) | 1 (8) |
ECOG PS | |||
0 | 2 (67) | 5 (83) | 2 (15) |
1 | 1 (33) | 1 (17) | 11 (85) |
Extent of disease | |||
Locally advanced | 0 (0) | 0 (0) | 2 (15) |
Metastatic | 3 (100) | 6 (100) | 11 (85) |
Location of primary | |||
Head | 2 (67) | 2 (33) | 4 (31) |
Body or tail | 1 (33) | 2 (33) | 9 (69) |
Not reported | 0 (0) | 2 (33) | 0 (0) |
Site of metastases | |||
Liver | 3 (100) | 5 (83) | 10 (77) |
Lung | 0 (0) | 2 (33) | 0 (0) |
Peritoneal | 0 (0) | 0 (0) | 3 (23) |
Skeleton | 0 (0) | 2 (33) | 0 (0) |
Other | 0 (0) | 0 (0) | 1 (8) |
Prior radiotherapies | |||
No | 3 (100) | 6 (100) | 11 (84) |
Yes | 0 (0) | 0 (0) | 1 (8) |
Not reported | 0 (0) | 0 (0) | 1 (8) |